DK1641434T3 - Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf - Google Patents
Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat derafInfo
- Publication number
- DK1641434T3 DK1641434T3 DK04743222T DK04743222T DK1641434T3 DK 1641434 T3 DK1641434 T3 DK 1641434T3 DK 04743222 T DK04743222 T DK 04743222T DK 04743222 T DK04743222 T DK 04743222T DK 1641434 T3 DK1641434 T3 DK 1641434T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivative
- pharmaceutical formulations
- protein containing
- intranasal administration
- containing chitosan
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0315632.0A GB0315632D0 (en) | 2003-07-04 | 2003-07-04 | Pharmaceutical formulations |
| PCT/GB2004/002876 WO2005004838A1 (en) | 2003-07-04 | 2004-07-02 | Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1641434T3 true DK1641434T3 (da) | 2009-04-06 |
Family
ID=27741549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04743222T DK1641434T3 (da) | 2003-07-04 | 2004-07-02 | Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7662403B2 (de) |
| EP (1) | EP1641434B1 (de) |
| AT (1) | ATE417599T1 (de) |
| AU (1) | AU2004255515B2 (de) |
| CA (1) | CA2531239C (de) |
| DE (1) | DE602004018496D1 (de) |
| DK (1) | DK1641434T3 (de) |
| ES (1) | ES2319995T3 (de) |
| GB (1) | GB0315632D0 (de) |
| NZ (1) | NZ544718A (de) |
| PL (1) | PL1641434T3 (de) |
| PT (1) | PT1641434E (de) |
| WO (1) | WO2005004838A1 (de) |
| ZA (1) | ZA200600027B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| US20090136505A1 (en) * | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| CA2657581A1 (en) * | 2006-07-11 | 2008-01-17 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
| US20080182819A1 (en) * | 2007-01-29 | 2008-07-31 | Act Iii Licensing, Llc | Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders |
| GB0812742D0 (en) | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
| WO2010056896A1 (en) | 2008-11-12 | 2010-05-20 | Synedgen, Inc. | Chitosan derivatives to treat animals or optimize animal health |
| WO2013078396A2 (en) * | 2011-11-23 | 2013-05-30 | Durect Corporation | Radiation-sterilized biodegradable drug delivery compositions |
| GB201319437D0 (en) * | 2013-11-04 | 2013-12-18 | Nanomerics Ltd | Delivery of drugs |
| JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
| US10111836B2 (en) | 2015-02-01 | 2018-10-30 | Orsenix Holdings Bv | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| CN112601541A (zh) * | 2018-06-22 | 2021-04-02 | 比欧拉利克斯有限公司 | 口服给药的生物聚合物制剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
| GB8904370D0 (en) | 1989-02-25 | 1989-04-12 | Cosmas Damian Ltd | Liquid delivery compositions |
| JPH07118170A (ja) * | 1993-10-19 | 1995-05-09 | Dot:Kk | 経鼻吸収薬物用キャリヤ、生理活性ペプチド組成物およびその製造法 |
| US20010053359A1 (en) * | 1994-07-26 | 2001-12-20 | Peter Watts | Drug delivery composition for the nasal administration of antiviral agents |
| GB9416884D0 (en) | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
| GB9419979D0 (en) | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
| SE9403905D0 (sv) * | 1994-11-14 | 1994-11-14 | Astra Ab | New formulations |
| GB9522351D0 (en) | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| ES2205177T5 (es) | 1996-02-27 | 2007-08-01 | Teijin Limited | Composicion en polvo para administracion nasal. |
| US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| GB2330534B (en) | 1996-07-10 | 2000-09-06 | Danbiosyst Uk | Gene therapy delivery system for targeting to endothelia |
| GB9700624D0 (en) * | 1997-01-14 | 1997-03-05 | Danbiosyst Uk | Drug delivery composition |
| GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| GB9713980D0 (en) | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| DE69930509T2 (de) * | 1998-07-08 | 2006-11-30 | Kirin-Amgen Inc., Wilmington | Pulverförmiges präparat zur anwendung auf schleimhäuten welches ein polymeres arzneimittel enthält |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| GB9924797D0 (en) | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
| US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| PL207845B1 (pl) | 2000-07-31 | 2011-02-28 | Nycomed Danmark As | Spray donosowy do dostarczania kompozycji farmaceutycznej zawierającej fentanyl i zastosowanie soli fentanylu do wytwarzania środka leczniczego |
| EP1458362A4 (de) * | 2001-11-19 | 2006-01-18 | Becton Dickinson Co | Pharmazeutische zusammensetzungen in teilchenform |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
-
2003
- 2003-07-04 GB GBGB0315632.0A patent/GB0315632D0/en not_active Ceased
-
2004
- 2004-07-02 AU AU2004255515A patent/AU2004255515B2/en not_active Ceased
- 2004-07-02 DK DK04743222T patent/DK1641434T3/da active
- 2004-07-02 CA CA2531239A patent/CA2531239C/en not_active Expired - Fee Related
- 2004-07-02 EP EP04743222A patent/EP1641434B1/de not_active Expired - Lifetime
- 2004-07-02 PL PL04743222T patent/PL1641434T3/pl unknown
- 2004-07-02 NZ NZ544718A patent/NZ544718A/en not_active IP Right Cessation
- 2004-07-02 AT AT04743222T patent/ATE417599T1/de active
- 2004-07-02 PT PT04743222T patent/PT1641434E/pt unknown
- 2004-07-02 ES ES04743222T patent/ES2319995T3/es not_active Expired - Lifetime
- 2004-07-02 WO PCT/GB2004/002876 patent/WO2005004838A1/en active Application Filing
- 2004-07-02 DE DE602004018496T patent/DE602004018496D1/de not_active Expired - Lifetime
-
2006
- 2006-01-03 ZA ZA200600027A patent/ZA200600027B/xx unknown
- 2006-01-04 US US11/325,073 patent/US7662403B2/en not_active Expired - Fee Related
-
2009
- 2009-09-30 US US12/570,039 patent/US8481070B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7662403B2 (en) | 2010-02-16 |
| WO2005004838A8 (en) | 2005-03-17 |
| PL1641434T3 (pl) | 2009-08-31 |
| CA2531239C (en) | 2011-05-24 |
| PT1641434E (pt) | 2009-03-19 |
| DE602004018496D1 (de) | 2009-01-29 |
| NZ544718A (en) | 2009-06-26 |
| US20100021553A1 (en) | 2010-01-28 |
| ATE417599T1 (de) | 2009-01-15 |
| CA2531239A1 (en) | 2005-01-20 |
| US8481070B2 (en) | 2013-07-09 |
| ZA200600027B (en) | 2009-08-26 |
| EP1641434A1 (de) | 2006-04-05 |
| AU2004255515B2 (en) | 2009-04-30 |
| AU2004255515A2 (en) | 2005-01-20 |
| EP1641434B1 (de) | 2008-12-17 |
| ES2319995T3 (es) | 2009-05-18 |
| WO2005004838A1 (en) | 2005-01-20 |
| AU2004255515A1 (en) | 2005-01-20 |
| GB0315632D0 (en) | 2003-08-13 |
| US20060120973A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600027B (en) | Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof | |
| CY1108875T1 (el) | Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα | |
| BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
| WO2002092147A3 (en) | Optimization of the molecular properties and formulation of proteins delivered by inhalation | |
| CY1105120T1 (el) | Η αντιμετωπιση αναπνευστικων νοσων | |
| AU2003295614A1 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
| DK1389137T3 (da) | Sammensætninger til lungelægemiddellevering af protein | |
| DK1207756T3 (da) | Anvendelse af spinosad eller en formulering, der omfatter spinosad | |
| EE05089B1 (et) | Amiidasendatud imidasokinoliinid ja neid sisaldavad farmatseutilised preparaadid | |
| DK1066044T3 (da) | Dextranformuleringer til behandling af inflammatoriske ledsygdomme | |
| EE05074B1 (et) | Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid | |
| DE69528057T2 (de) | Tocopherolzusammensetzungen zur Abgabe von biologisch aktiven Substanzen | |
| DK0749317T3 (da) | Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein | |
| BR9809448A (pt) | Produtos aerossóis medicinais. | |
| ATE422356T1 (de) | Pharmazeutische zubereitungen | |
| NO20065860L (no) | Stabiliserte flytende interferonformuleringer | |
| NO20064521L (no) | Framgangsmate og blanding for behandling av rhinitt | |
| DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| DK1392254T3 (da) | Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler | |
| BR0313148A (pt) | Formulações de liberação controlada compreendendo lamotrigina | |
| BRPI0415557A (pt) | formulação contendo ingrediente ativo farmacêutico com revestimento | |
| NO20052408L (no) | Farmasoytisk formulering av olanzapin | |
| ATE240717T1 (de) | Wässrige formulierung zur nasalen verabreichung | |
| WO2003079993A3 (en) | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| ATE464878T1 (de) | Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl |